Hemp-derived CBD safety studies
Pro Research Analysisby 
Searched over 200M research papers
Overview of Hemp-Derived CBD Safety Studies
Research on the safety of hemp-derived cannabidiol (CBD) has expanded rapidly, with studies focusing on a range of health outcomes, including neurological, hepatic, reproductive, and general toxicity. While CBD is generally considered well-tolerated, there are important considerations and data gaps regarding its safety profile, especially with long-term or high-dose use .
General Toxicity and Tolerability of CBD
Multiple animal studies have shown that oral administration of hemp-derived CBD, even at relatively high doses, is well tolerated. In 14- and 90-day studies with rats, no significant adverse effects were observed at doses up to 140–150 mg/kg body weight per day, and any minor liver or adrenal changes resolved after a recovery period . Similarly, a proprietary hemp oil extract with high CBD content showed no significant adverse effects in rats, with only reversible, adaptive liver changes at high doses. The no observed adverse effect level (NOAEL) was determined to be 185.9 mg/kg body weight per day . Another 90-day study using a full-spectrum CBD-rich hemp extract found no adverse effects on organ or body weight, behavior, or mortality, though some reversible, sex-dependent changes in blood and liver/kidney markers were noted .
Reproductive and Developmental Toxicity
Reproductive and developmental toxicity is a key area where data have been lacking. Recent studies in rats found that high doses of CBD (300 mg/kg/day) led to maternal toxicity, decreased body weight, and some developmental effects such as lower pup weights and occasional litter loss. However, no effects were seen on testosterone levels, reproductive performance, or organs at lower doses. The NOAEL for reproductive and developmental toxicity was identified as 100 mg/kg/day . These findings highlight the need for further research, especially in humans, to clarify potential risks 14.
Neurological and Other Health Outcomes
Neurological outcomes are the most frequently studied area in CBD safety research, with most studies reporting few adverse events. Some studies have also examined carcinogenic, hepatic, and gastrointestinal outcomes, but these are less common. Immune system effects are emerging as a new area of interest .
Human Studies and Perceived Effects
Short-term human studies with commercial broad-spectrum CBD products (containing negligible THC) have shown no adverse events and no detectable THC or its metabolites in urine after two weeks of daily use. Participants reported improvements in sleep and pain, with no negative effects on physical or mental well-being . However, these studies are limited in duration and sample size.
Product Contamination and Regulatory Concerns
A significant safety concern is the contamination of CBD products with delta-9-tetrahydrocannabinol (THC). Analyses of commercial products have found that many contain detectable levels of THC, even those labeled as "THC-free." Some products exceeded the lowest observed adverse effect level for THC, raising the risk of unintended psychoactive effects and potential legal consequences 710. The lack of regulation and inconsistent labeling further complicates consumer safety .
Conclusion
Current evidence suggests that hemp-derived CBD is generally well tolerated in both animal and short-term human studies, with most adverse effects being mild, reversible, and occurring at high doses. However, there are important gaps in knowledge, particularly regarding long-term use, reproductive and developmental toxicity, and the impact of product contamination with THC. More rigorous, guideline-compliant studies—especially in humans—are needed to fully establish the safety profile of CBD and to address regulatory and quality control issues in commercial products 1234+4 MORE.
Sources and full results
Most relevant research papers on this topic
Cannabidiol Safety Data: A Systematic Mapping Study
This systematic map of CBD safety data highlights the need for further research on reproductive and developmental toxicity, as well as immune outcomes, to determine a safe CBD intake level for consumer use.
Oral toxicity evaluation of cannabidiol.
CBD is well tolerated when administered orally at doses up to 150 mg/kg-bw/d in rats, with no adverse effects observed after 28 days of recovery.
DOI
Reproductive and developmental toxicity evaluation of cannabidiol.
CBD isolate may cause severe maternal toxicity in rats, with no effects on testosterone concentrations, reproductive performance, or reproductive organs.
DOI